Literature DB >> 29247664

Fate of PEGylated antibody fragments following delivery to the lungs: Influence of delivery site, PEG size and lung inflammation.

Harshad P Patil1, Danielle Freches1, Linda Karmani2, Gregg A Duncan3, Bernard Ucakar1, Jung Soo Suk3, Justin Hanes4, Bernard Gallez2, Rita Vanbever5.   

Abstract

Pulmonary administration of anti-cytokine antibodies offers a targeted therapy in asthma. However, the rapid elimination of proteins from the lungs limits the efficacy of inhaled medications. PEGylation has been shown to increase the residence time of anti-interleukin (IL)-17A and anti-IL-13 antibody fragments in the lungs and to improve their therapeutic efficacy. Yet, little is known about the factors that affect the residence time of PEGylated antibody fragments in the lungs following pulmonary delivery. In this study, we showed that the molecular weight of polyethylene glycol (PEG), 20kDa or 40kDa, had a moderate effect on the residence time of an anti-IL-17A Fab' fragment in the lungs of mice. By contrast, the site of delivery of the anti-IL-17A and anti-IL-13 Fab' fragments within the lungs had a major impact on their residence time, with the deeper the delivery, the more prolonged the residence time. The nature of the Fab' fragment had an influence on its residence time as well and the anti-IL-17A Fab' benefited more from PEGylation than the anti-IL-13 Fab' did. Acute lung inflammation slightly shortened the residence time of the anti-IL-17A and anti-IL-13 Fab' fragments in the lungs but PEGylation was able to prolong their presence in both the healthy and inflamed lungs. Antibody fragments were predominately located within the airway lumen rather than the lung parenchyma. Transport experiments on monolayers of Calu-3 cells and studies of fluorescence recovery after photobleaching in respiratory mucus showed that mechanisms involved in the prolonged presence of PEGylated Fab' in the airway lumen might include binding to the mucus, reduced uptake by respiratory cells and reduced transport across lung epithelia. Finally, using I125-labeled anti-IL-17A Fab', we showed that the protein fragment hardly penetrated into the lungs following subcutaneous injection, as opposed to pulmonary delivery.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anti-IL-13; Anti-IL-17A; Central airways; Lung inflammation; Lung periphery; Mucus; Polyethylene glycol; Residence time

Mesh:

Substances:

Year:  2017        PMID: 29247664     DOI: 10.1016/j.jconrel.2017.12.009

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  5 in total

1.  Temperature- and rigidity-mediated rapid transport of lipid nanovesicles in hydrogels.

Authors:  Miaorong Yu; Wenyi Song; Falin Tian; Zhuo Dai; Quanlei Zhu; Ejaj Ahmad; Shiyan Guo; Chunliu Zhu; Haijun Zhong; Yongchun Yuan; Tao Zhang; Xin Yi; Xinghua Shi; Yong Gan; Huajian Gao
Journal:  Proc Natl Acad Sci U S A       Date:  2019-03-05       Impact factor: 11.205

Review 2.  Avoiding a Sticky Situation: Bypassing the Mucus Barrier for Improved Local Drug Delivery.

Authors:  Hannah C Zierden; Aditya Josyula; Rachel L Shapiro; Henry T Hsueh; Justin Hanes; Laura M Ensign
Journal:  Trends Mol Med       Date:  2021-01-04       Impact factor: 11.951

3.  In Vitro and In Vivo Assessment of PEGylated PEI for Anti-IL-8/CxCL-1 siRNA Delivery to the Lungs.

Authors:  Alan J Hibbitts; Joanne M Ramsey; James Barlow; Ronan MacLoughlin; Sally-Ann Cryan
Journal:  Nanomaterials (Basel)       Date:  2020-06-27       Impact factor: 5.076

Review 4.  Therapeutic antibodies - natural and pathological barriers and strategies to overcome them.

Authors:  Yara Al Ojaimi; Timothée Blin; Juliette Lamamy; Matthieu Gracia; Aubin Pitiot; Caroline Denevault-Sabourin; Nicolas Joubert; Jean-Pierre Pouget; Valérie Gouilleux-Gruart; Nathalie Heuzé-Vourc'h; Débora Lanznaster; Sophie Poty; Thomas Sécher
Journal:  Pharmacol Ther       Date:  2021-10-20       Impact factor: 13.400

5.  PEGylated green halloysite/spinel ferrite nanocomposites for pH sensitive delivery of dexamethasone: A potential pulmonary drug delivery treatment option for COVID-19.

Authors:  B Rabindran Jermy; Vijaya Ravinayagam; D Almohazey; W A Alamoudi; H Dafalla; Sultan Akhtar; Gazali Tanimu
Journal:  Appl Clay Sci       Date:  2021-11-09       Impact factor: 5.467

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.